SCHEMBL6156444

SCHEMBL6156444

N=C(N)c1cccc(N(NC(=O)Nc2ccc(N3CCCCC3=O)cc2)c2ccccc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 7/20 0.62
SMN1; SMN2 Q16637 4/20 0.47
NPC1 O15118 3/20 0.47
ALDH1A1 P00352 3/20 0.47
RAB9A P51151 2/20 0.47
TP53 P04637 1/20 0.47
GLA P06280 1/20 0.47
PKM P14618 1/20 0.47
TSHR P16473 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM1A O60341 1/20 0.45
MAOB P27338 1/20 0.45
MAPT P10636 3/20 0.45
PRSS1 P07477 2/20 0.44
F2 P00734 1/20 0.44
HPGD P15428 2/20 0.42
LMNA P02545 1/20 0.42
HPGDS O60760 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6156656 0.87 F10 (0.47) F10SMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL6156115 0.84 TSHR (0.46) F10SMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL6157131 0.84 TSHR (0.46) F10SMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL6157482 0.81 F10 (0.68) F10SMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL6156891 0.78 F10 (0.39) F10SMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL6156697 0.78 SMN1; SMN2 (0.47) F10SMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL5165960 0.76 F10 (1.00) F10SMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL5166204 0.76 F10 (1.00) F10SMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL5163366 0.76 F10 (0.71) F10SMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL5164409 0.76 F10 (0.73) F10SMN1; SMN2NPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US claimed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP claimed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO claimed
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases SERPINC1, F11, F12 F10 6/4885SMN1; SMN2 3250/4885NPC1 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.